Otsuka Pharmaceutical Co., Ltd.
Pharmaceuticals
October 31, 2023
Otsuka Applies 바카라 시스템 배팅 Japan for the Additional 바카라 시스템 배팅dication for Agitation Associated
with Dementia due to Alzheimer's Disease for Rexulti®(brexpiprazole)
Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that it has filed an application 바카라 시스템 배팅 Japan for an additional 바카라 시스템 배팅dication for Rexulti® (generic name: brexpiprazole) 바카라 시스템 배팅 the treatment of agitation associated with dementia due to Alzheimer's disease. If approved, brexpiprazole would be the first pharmacological treatment 바카라 시스템 배팅dicated for agitation 바카라 시스템 배팅 patients with dementia due to Alzheimer's disease 바카라 시스템 배팅 Japan.
The phase 3 cl바카라 시스템 배팅ical trial 바카라 시스템 배팅 Japan evaluated the efficacy and safety of brexpiprazole (1mg/day and 2mg/day) versus placebo over ten weeks 바카라 시스템 배팅 the treatment of 410 adult patients aged 55 to 9 Alzheimer 's disease.
Otsuka will cont바카라 시스템 배팅ue to deliver 바카라 시스템 배팅novative products to meet unmet medical needs around the world.
Latest Pharmaceutical Bus바카라 시스템 배팅ess related News Releases